Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information (Tables)

v3.21.2
Note 13 - Segment Information (Tables)
3 Months Ended
Sep. 30, 2021
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   

Quarter Ended

 
   

September 30,

 
   

2021

   

2020

 

Net sales:

               

Protein Sciences

  $ 197,186     $ 154,446  

Diagnostics and Genomics

    60,985       50,125  

Intersegment

    (452

)

    (372

)

Consolidated net sales

  $ 257,719     $ 204,199  

Operating income:

               

Protein Sciences

  $ 90,100     $ 70,352  

Diagnostics and Genomics

    7,463       8,674  

Segment operating income

    97,563       79,026  
Costs recognized on sale of acquired inventory     (1,512)       -  

Amortization of acquisition related intangible assets

    (18,389

)

    (15,501

)

Impact of partially owned consolidated subsidiaries     (1,562 )     -  

Acquisition related expenses

    2,377

 

    (136

)

Stock-based compensation, inclusive of employer taxes

    (13,860

)

    (13,333

)

Restructuring costs     (1,185 )     -  

Corporate general, selling, and administrative expenses

    (210

)

    (964

)

Consolidated operating income

  $ 63,222     $ 49,092